WASHINGTON — The Department of Health and Human Services is moving forward with a policy that could require drug companies to put the price of their medicine in advertisements.
The White House Office of Management and Budget received a draft regulation from HHS this week titled “Medicare and Medicaid Programs; Regulation to Require Drug Pricing Transparency.” An HHS spokesperson declined to comment on what the regulation would do, but lobbyists told STAT that it relates to the policy of requiring drug price information in ads.
